Your browser doesn't support javascript.
loading
Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Agrawal, Rishabh; Dey, Asoke; Datta, Sujay; Nassar, Ana; Grubb, William; Traughber, Bryan; Biswas, Tithi; Ove, Roger; Podder, Tarun.
Affiliation
  • Agrawal R; Department of Radiation Oncology, Medical College of Georgia, Augusta, GA 30912, USA.
  • Dey A; Department of Management, University of Akron, Akron, OH 44325, USA.
  • Datta S; Department of Statistics, University of Akron, Akron, OH 44325, USA.
  • Nassar A; Department of Radiation Oncology, Medical College of Georgia, Augusta, GA 30912, USA.
  • Grubb W; Department of Radiation Oncology, Medical College of Georgia, Augusta, GA 30912, USA.
  • Traughber B; Department of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Biswas T; Mayo Clinic, Rochester, MN 55905, USA.
  • Ove R; Department of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Podder T; University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.
Cancers (Basel) ; 14(22)2022 Nov 09.
Article de En | MEDLINE | ID: mdl-36428595
ABSTRACT

Background:

In this study, the utilization rates and survival outcomes of different radiotherapy techniques are compared in prostate cancer (PCa) patients stratified by risk group.

Methods:

We analyzed an extensive data set of N0, M0, non-surgical PCa patients diagnosed between 2004 and 2015 from the National Cancer Database (NCDB). Patients were grouped into six categories based on RT modality an intensity-modulated radiation therapy (IMRT) group with brachytherapy (BT) boost, IMRT with/without IMRT boost, proton therapy, stereotactic body radiation therapy (SBRT), low-dose-rate brachytherapy (BT LDR), and high-dose-rate brachytherapy (BT HDR). Patients were also stratified by the National Comprehensive Cancer Network (NCCN) guidelines low-risk (clinical stage T1−T2a, Gleason Score (GS) ≤ 6, and Prostate-Specific Antigen (PSA) < 10), intermediate-risk (clinical stage T2b or T2c, GS of 7, or PSA of 10−20), and high-risk (clinical stage T3−T4, or GS of 8−10, or PSA > 20). Overall survival (OS) probability was determined using a Kaplan−Meier estimator. Univariate and multivariate analyses were performed by risk group for the six treatment modalities.

Results:

The most utilized treatment modality for all PCa patients was IMRT (53.1%). Over the years, a steady increase in SBRT utilization was observed, whereas BT HDR usage declined. IMRT-treated patient groups exhibited relatively lower survival probability in all risk categories. A slightly better survival probability was observed for the proton therapy group. Hormonal therapy was used for a large number of patients in all risk groups.

Conclusion:

This study revealed that IMRT was the most common treatment modality for PCa patients. Brachytherapy, SBRT, and IMRT+BT exhibited similar survival rates, whereas proton showed slightly better overall survival across the three risk groups. However, analysis of the demographics indicates that these differences are at least in part due to selection bias.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Etiology_studies / Guideline / Risk_factors_studies Langue: En Journal: Cancers (Basel) Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Etiology_studies / Guideline / Risk_factors_studies Langue: En Journal: Cancers (Basel) Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...